Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

CanAssist Breast

Other Approval


CanAssist Breast is an IHC based prognostic test for early-stage breast cancer patients. The test offers vital insights about the tumor and aids to personalize a treatment plan specifically for each patient’s situation - including the risk of distant recurrence, the benefit from chemotherapy and whether the patient can be treated effectively with hormonal therapy alone. CanAssist Breast predicts cancer recurrence in hormone-positive patients in stages 1 and 2, through a machine learning-based algorithm that incorporates data from patient’s tumor biology, and clinico-pathological data (tumor size, tumor grade, and node status) to arrive at a comprehensive CanAssist Breast risk score. The test can stratify node negative (NO) and node-positive (NP) patients effectively across all ages, including early onset (<45 years) patients as well. This is the only test developed and validated on Indian patients.
Breast Cancer, HER2 Negative Breast Cancer, Hormone Receptor Positive Breast Cancer
ER (Estrogen receptor), HER-2 (Human epidermal growth factor receptor 2), PGR (Progesterone receptor)
Immunohistochemistry (IHC)